Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial

Yi-Long Wu,1 Chong-Rui Xu,1 Cheng-Ping Hu,2 Jifeng Feng,3 Shun Lu,4 Yunchao Huang,5 Wei Li,6 Mei Hou,7 Jian Hua Shi,8 Angela Märten,9 Jean Fan,10 Barbara Peil,11 Caicun Zhou12 1Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou,...

Full description

Bibliographic Details
Main Authors: Wu YL, Xu CR, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Märten A, Fan J, Peil B, Zhou C
Format: Article
Language:English
Published: Dove Medical Press 2018-11-01
Series:OncoTargets and Therapy
Subjects:
Afatinib
NSCLC
EGFR
first-line
Phase III
Chinese patients
Online Access:https://www.dovepress.com/afatinib-versus-gemcitabinecisplatin-for-first-line-treatment-of-chine-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/afatinib-versus-gemcitabinecisplatin-for-first-line-treatment-of-chine-peer-reviewed-article-OTT

Similar Items